HBP.TO
Helix BioPharma Corp. [HBP.TO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
HBP.TO Stock Summary
Top 10 Correlated ETFs
HBP.TO
Top 10 Correlated Stocks
HBP.TO
In the News
HBP.TO Financial details
Company Rating
-
Market Cap
40.08M
Income
-5.94M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
12 Jun 2024
P/E
-8.06
Forward P/E
-
PEG
2.9
P/S
-
P/B
76.99
P/C
-
P/FCF
-8.84
Quick Ratio
1.34
Current Ratio
1.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.03
EPS next Y
-
EPS next Q
-
EPS this Y
-19.9%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-45.37%
-
-
-
-
SMA20
-
SMA50
-10.11%
SMA100
-10.11%
Inst Own
-
Inst Trans
-
ROA
-313%
ROE
-815%
ROC
-9.54%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.15-0.26
52W High
-
52W Low
-
RSI
81
Rel Volume
0.55
Avg Volume
13.13K
Volume
7.22K
Perf Week
23.08%
Perf Month
1.05%
Perf Quarter
68.42%
Perf Half Y
-4.95%
-
-
-
-
Beta
-0.735
-
-
Volatility
0.06%, 0.03%
Prev Close
23.08%
Price
0.96
Change
23.08%
Company Profile
- Volume Average 13.13K
- Market Capitalization 40.08M
- Employee 9
- CEO Mr. Jacek Antas
- Headquarters Richmond Hill,ON,CA
- IPO Date 1996-08-13
-
Website
https://www.helixbiopharma.com 
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
